Cats and humans may look nothing alike, but deep inside their tumors, scientists have discovered something extraordinary.
In the largest genetic study of feline cancer to date, researchers analyzed 493 tumors from pet cats across 13 different cancer types, comparing tumor DNA with healthy tissue from the same animals. The work, published in Science in February 2026, examined feline versions of roughly 1,000 genes already associated with human cancer. PubMed Central (PMC)
What emerged was the first broad genetic map of cancer in domestic cats—and a striking picture of how much feline and human cancers can have in common.
Nearly 500 Tumors — 13 Different Cancers
Until recently, scientists knew surprisingly little about the mutations driving cancers in cats.
Cancer genomics in humans has transformed oncology by allowing some tumors to be treated according to their molecular alterations rather than only where they appear in the body. Dogs have also received growing attention from comparative-cancer researchers.
Cats remained relatively understudied.
The international team set out to change that.
Researchers studied cancers including mammary carcinoma, lymphoma, lung adenocarcinoma, osteosarcoma, colorectal cancer, pancreatic cancer, glioma, meningioma and several skin and oral cancers. PubMed Central (PMC)
Importantly, these weren’t cancers artificially created in laboratory animals.
They developed naturally in household pets.
That makes cats particularly interesting for comparative oncology because they live in complex environments, develop cancer spontaneously, have functioning immune systems and can share environmental exposures with humans. PubMed Central (PMC)
One Famous Cancer Gene Immediately Stood Out
The researchers identified 31 cancer driver genes across the feline tumors.
But one appeared more frequently than any other:
TP53.
TP53 is one of the most important tumor-suppressor genes in human biology. Its protein helps damaged cells respond to DNA damage and can prevent abnormal cells from continuing to divide.
When TP53 is disabled by mutations, that protection can disappear.
In the feline study, TP53 alterations appeared in roughly one-third of the tumors. Cornell researchers noted an intriguing comparison: a large human cancer dataset found TP53 mutations in approximately 34% of tumors. Cornell Chronicle
Even more interestingly, some mutations appeared in corresponding regions of the TP53 protein in cats and humans. PubMed Central (PMC)
The similarity wasn’t limited to a single gene.
Cats and Humans Share Several Cancer Drivers
Researchers identified parallels involving genes including:
TP53, FBXW7, CTNNB1 and PIK3CA.
These aren’t obscure genetic curiosities. Several are well-established players in human cancer biology.
Some mutation patterns were particularly similar when scientists compared corresponding feline and human cancers.
For example, certain PIK3CA mutations appeared in feline mammary tumors, while TP53 mutation patterns showed similarities in mammary cancer, osteosarcoma and oral squamous cell carcinoma. PubMed Central (PMC)
There were important differences too.
The researchers did not find the same pattern of activating RAS mutations commonly observed across various human cancers, illustrating why feline tumors shouldn’t simply be treated as miniature versions of human disease. ScienceDirect
Those differences may ultimately be just as informative as the similarities.
The Breast Cancer Connection Was Particularly Interesting
One of the study’s most intriguing findings involved feline mammary carcinoma—the cat counterpart to human breast cancer.
Researchers identified seven driver genes in feline mammary tumors.
One stood out dramatically.
FBXW7 was altered in more than half of the feline mammary tumors studied. Cornell Chronicle
FBXW7 mutations also occur in human breast cancers and have been associated with poorer outcomes in some human clinical data.
That prompted the scientists to ask a much more exciting question:
Could knowing a cat tumor’s mutation tell veterinarians which drug might work against it?
They tested the idea in the laboratory.
They Grew Tiny Cat Tumors in the Lab
Researchers created tumoroids—three-dimensional cultures derived from feline tumor cells.
These miniature tumor models allowed them to test how cancers carrying particular mutations responded to different treatments.
And something remarkable happened.
Feline mammary tumoroids carrying FBXW7 mutations showed increased sensitivity to vinca alkaloids, a class of chemotherapy drugs. ScienceDirect
That doesn’t mean veterinarians can immediately sequence every cat’s tumor and prescribe a matching medication.
The finding needs further validation and clinical investigation.
But it demonstrates the principle behind precision veterinary oncology:
find the mutation driving a particular tumor, then investigate treatments capable of exploiting that vulnerability.
Treat the Mutation, Not Simply “Cat Cancer”
This is essentially the direction human oncology has been moving for years.
Two tumors arising in the same organ may contain very different molecular alterations.
Conversely, tumors arising in completely different tissues can sometimes share actionable mutations.
Genomic profiling can therefore help researchers ask a more precise question than:
“What type of cancer is this?”
They can also ask:
“What molecular alterations are driving this particular cancer?”
Cornell co-author Dr. Latasha Ludwig described the emerging idea as moving toward treatment of the specific mutation rather than focusing only on the species or even the tumor type. Cornell Chronicle
For cats, that’s potentially a major change.
Skin Cancer Revealed Another Familiar Story
The genetic map also contained clues about what caused some tumors.
Researchers detected mutational signatures associated with ultraviolet radiation in feline cutaneous squamous cell carcinoma.
That’s particularly fascinating because UV radiation is also an important cause of human skin cancer. Cornell Chronicle
Cats—particularly those with lightly pigmented skin—can develop UV-associated tumors on sun-exposed areas.
Here again, two very different species appear to be experiencing some of the same cancer biology in response to a shared environmental exposure.
Why Cats May Teach Us Things Laboratory Mice Cannot
Laboratory mice remain enormously important to cancer research.
But naturally occurring cancer in companion animals offers something different.
A pet cat isn’t genetically identical to thousands of other cats in a laboratory colony.
It ages naturally.
It develops other health conditions.
It lives in a real household.
It encounters environmental exposures.
And its cancer develops spontaneously rather than being deliberately induced.
That combination makes companion animals potentially valuable intermediate models between controlled laboratory experiments and human clinical studies. PubMed Central (PMC)
Cats could therefore contribute to what researchers call comparative oncology—studying cancer across species to discover shared biological mechanisms.
And Information Could Travel in Both Directions
That’s perhaps the most exciting idea behind the research.
Human oncology already possesses enormous databases linking mutations with treatments and clinical outcomes.
If feline tumors contain some of those same molecular alterations, existing knowledge could potentially help researchers identify treatments worth investigating for cats.
But the information could travel the other way too.
Cats naturally develop certain cancers that resemble human diseases.
Observing how those tumors progress—and eventually how genetically characterized tumors respond to treatments—could reveal vulnerabilities relevant to human cancer research.
It’s part of the broader One Medicine/One Health concept: discoveries in human and veterinary medicine informing one another. PubMed Central (PMC)
It Could Eventually Change Cancer Treatment for Cats
For families facing a feline cancer diagnosis today, treatment options can still be limited depending on the tumor.
Genomic information could eventually help veterinarians distinguish tumors that merely look similar under a microscope but behave differently at the molecular level.
The study also identified potentially actionable alterations beyond mammary cancer.
For example, mutations involving KIT appeared in about 40% of feline cutaneous mast-cell tumors in the study, making that pathway particularly interesting because drugs targeting KIT already exist. PubMed Central (PMC)
That doesn’t establish that every cat carrying such a mutation will respond to a particular drug.
But it gives researchers a rational target to investigate.
And that’s how precision oncology begins.
There’s Still a Lot We Don’t Know
This enormous genetic map is a starting point, not a finished treatment manual.
The researchers specifically focused on feline counterparts of roughly 1,000 genes already associated with human cancer.
That means uniquely feline cancer drivers could have been missed. PubMed Central (PMC)
Cats and humans also metabolize drugs differently, meaning a treatment that works against a molecular target in humans cannot simply be assumed to have the same efficacy, dose or safety profile in cats. ScienceDirect
Clinical trials will be needed before genomic findings can routinely guide feline cancer treatment.
But scientists now have something they largely lacked before:
a map.
The Bigger Picture
For decades, cancer research has often flowed in one direction—from laboratory animals toward humans.
This study suggests a much more interconnected future.
Cats develop cancer naturally.
They share parts of our environment.
Their tumors can acquire mutations remarkably similar to mutations appearing in human cancers.
And now scientists have mapped many of those changes across hundreds of real feline tumors.
The immediate hope is better cancer treatment for cats.
The larger possibility is even more intriguing:
understanding why cancer behaves similarly—and differently—across species could reveal vulnerabilities that neither human nor veterinary oncology would discover as quickly alone.
A household cat curled up on the couch may seem very far removed from a human cancer laboratory.
At the level of tumor DNA, the distance is surprisingly small. PubMed Central (PMC)
If you’re interested in other stories that have people talking, check out how Usha Vance stepped back into the spotlight after welcoming her fourth child, or see what had viewers looking twice when Madonna returned to the VMAs and the 3 controversies that everyone was talking about after the 2026 MTV VMAs.
